Trevor J Pugh1, James M Fink2, Xinyan Lu3, Susan Mathew4, Joyce Murata-Collins5, Pascale Willem6, Min Fang7. 1. Princess Margaret Cancer Centre, University Health Network; Ontario Institute for Cancer Research; and Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada. Electronic address: trevor.pugh@utoronto.ca. 2. Department of Laboratory Medicine and Pathology, Hennepin County Medical Center, Minneapolis, MN, USA. 3. Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 4. Department of Pathology, Weill Cornell Medicine, New York, NY, USA. 5. Department of Pathology, City of Hope National Medical Center, Duarte, CA, USA. 6. Department of Haematology and Molecular Medicine, Faculty of Health Sciences, University of the Witwatersrand and the National Health Laboratory Service, Johannesburg, South Africa. 7. Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA. Electronic address: mfang@fredhutch.org.
Abstract
BACKGROUND: Plasma cell neoplasms (PCNs) encompass a spectrum of disorders including monoclonal gammopathy of undetermined significance, smoldering myeloma, plasma cell myeloma, and plasma cell leukemia. Molecular subtypes have been defined by recurrent cytogenetic abnormalities and somatic mutations that are prognostic and predictive. Karyotype and fluorescence in situ hybridization (FISH) have historically been used to guide management; however, new technologies and markers raise the need to reassess current testing algorithms. METHODS: We convened a panel of representatives from international clinical laboratories to capture current state-of-the-art testing from published reports and to put forward recommendations for cytogenomic testing of plasma cell neoplasms. We reviewed 65 papers applying FISH, chromosomal microarray (CMA), next-generation sequencing, and gene expression profiling for plasma cell neoplasm diagnosis and prognosis. We also performed a survey of our peers to capture current laboratory practice employed outside our working group. RESULTS: Plasma cell enrichment is widely used prior to FISH testing, most commonly by magnetic bead selection. A variety of strategies for direct, short- and long-term cell culture are employed to ensure clonal representation for karyotyping. Testing of clinically-informative 1p/1q, del(13q) and del(17p) are common using karyotype, FISH and, increasingly, CMA testing. FISH for a variety of clinically-informative balanced IGH rearrangements is prevalent. Literature review found that CMA analysis can detect abnormalities in 85-100% of patients with PCNs; more specifically, in 5-53% (median 14%) of cases otherwise normal by FISH and cytogenetics. CMA results in plasma cell neoplasms are usually complex, with alteration counts ranging from 1 to 74 (median 10-20), primarily affecting loci not covered by FISH testing. Emerging biomarkers include structural alterations of MYC as well as somatic mutations of KRAS, NRAS, BRAF, and TP53. Together, these may be measured in a comprehensive manner by a combination of newer technologies including CMA and next-generation sequencing (NGS). Our survey suggests most laboratories have, or are soon to have, clinical CMA platforms, with a desire to move to NGS assays in the future. CONCLUSION: We present an overview of current practices in plasma cell neoplasm testing as well as an algorithm for integrated FISH and CMA testing to guide treatment of this disease.
BACKGROUND: Plasma cell neoplasms (PCNs) encompass a spectrum of disorders including monoclonal gammopathy of undetermined significance, smoldering myeloma, plasma cell myeloma, and plasma cell leukemia. Molecular subtypes have been defined by recurrent cytogenetic abnormalities and somatic mutations that are prognostic and predictive. Karyotype and fluorescence in situ hybridization (FISH) have historically been used to guide management; however, new technologies and markers raise the need to reassess current testing algorithms. METHODS: We convened a panel of representatives from international clinical laboratories to capture current state-of-the-art testing from published reports and to put forward recommendations for cytogenomic testing of plasma cell neoplasms. We reviewed 65 papers applying FISH, chromosomal microarray (CMA), next-generation sequencing, and gene expression profiling for plasma cell neoplasm diagnosis and prognosis. We also performed a survey of our peers to capture current laboratory practice employed outside our working group. RESULTS: Plasma cell enrichment is widely used prior to FISH testing, most commonly by magnetic bead selection. A variety of strategies for direct, short- and long-term cell culture are employed to ensure clonal representation for karyotyping. Testing of clinically-informative 1p/1q, del(13q) and del(17p) are common using karyotype, FISH and, increasingly, CMA testing. FISH for a variety of clinically-informative balanced IGH rearrangements is prevalent. Literature review found that CMA analysis can detect abnormalities in 85-100% of patients with PCNs; more specifically, in 5-53% (median 14%) of cases otherwise normal by FISH and cytogenetics. CMA results in plasma cell neoplasms are usually complex, with alteration counts ranging from 1 to 74 (median 10-20), primarily affecting loci not covered by FISH testing. Emerging biomarkers include structural alterations of MYC as well as somatic mutations of KRAS, NRAS, BRAF, and TP53. Together, these may be measured in a comprehensive manner by a combination of newer technologies including CMA and next-generation sequencing (NGS). Our survey suggests most laboratories have, or are soon to have, clinical CMA platforms, with a desire to move to NGS assays in the future. CONCLUSION: We present an overview of current practices in plasma cell neoplasm testing as well as an algorithm for integrated FISH and CMA testing to guide treatment of this disease.
Authors: F Nguyen-Khac; A Bidet; A Daudignon; M Lafage-Pochitaloff; G Ameye; C Bilhou-Nabéra; E Chapiro; M A Collonge-Rame; W Cuccuini; N Douet-Guilbert; V Eclache; I Luquet; L Michaux; N Nadal; D Penther; B Quilichini; C Terre; C Lefebvre; M-B Troadec; L Véronèse Journal: Leukemia Date: 2022-04-16 Impact factor: 12.883
Authors: James Smadbeck; Jess F Peterson; Kathryn E Pearce; Beth A Pitel; Andrea Lebron Figueroa; Michael Timm; Dragan Jevremovic; Min Shi; A Keith Stewart; Esteban Braggio; Daniel L Riggs; P Leif Bergsagel; George Vasmatzis; Hutton M Kearney; Nicole L Hoppman; Rhett P Ketterling; Shaji Kumar; S Vincent Rajkumar; Patricia T Greipp; Linda B Baughn Journal: Blood Cancer J Date: 2019-12-16 Impact factor: 11.037
Authors: Alexander C Leeksma; Panagiotis Baliakas; Theodoros Moysiadis; Anna Puiggros; Karla Plevova; Anne-Marie Van der Kevie-Kersemaekers; Hidde Posthuma; Ana E Rodriguez-Vicente; Anh Nhi Tran; Gisela Barbany; Larry Mansouri; Rebeqa Gunnarsson; Helen Parker; Eva Van den Berg; Mar Bellido; Zadie Davis; Meaghan Wall; Ilaria Scarpelli; Anders Österborg; Lotta Hansson; Marie Jarosova; Paolo Ghia; Pino Poddighe; Blanca Espinet; Sarka Pospisilova; Constantine Tam; Loïc Ysebaert; Florence Nguyen-Khac; David Oscier; Claudia Haferlach; Jacqueline Schoumans; Marian Stevens-Kroef; Eric Eldering; Kostas Stamatopoulos; Richard Rosenquist; Jonathan C Strefford; Clemens Mellink; Arnon P Kater Journal: Haematologica Date: 2021-01-01 Impact factor: 9.941